The overall mission of the Virology/Immunology Core is to enhance HIV-related research andpromote collaborations among HIV investigators, by providing improved access to virologic andimmunologic assays, clinical specimens, and recombinant DMA constructs.
The specific aims of this Core are:1. To provide a centralized repository for clinical specimens and HIV-related recombinant DMAconstructs that can be used by clinical, behavioral, and laboratory investigators.2. To centralize, and improve access to, state-of-the-art virologic assays for clinical, behavioral,and laboratory investigators.3. To provide a centralized facility that produces recombinant proteins relevant to HIV research.4. To provide expertise in the design and interpretation of flow cytometry assays, and to improveaccess to the shared instrumentation necessary to conduct these studies.5. To provide improved access to existing URMC core facilities.This core will utilize and augment already existing infrastructures, such as those in the Cold StorageFacility (Aim 1), Infectious Diseases Unit laboratories (Aim 2), Human Immunology Center (Aim 4), andexisting core facilities (Aim 5) at the URMC. In addition, we will centralize expression of certainrecombinant proteins (Aim 3), in order to provide economy of scale to investigators that use them in HIVrelatedresearch. The Virology/Immunology Core will implement the overall mission of the UR D-CFARby supporting a broad base of investigators from the UR and its international collaborators in SouthAfrica, and promoting interdisciplinary collaborations among them.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
1P30AI078498-01
Application #
7479042
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Project Start
2008-05-01
Project End
2013-04-30
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
1
Fiscal Year
2008
Total Cost
$121,712
Indirect Cost
Name
University of Rochester
Department
Type
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Dompreh, Albert; Tang, Xiaoli; Zhou, Jianlin et al. (2018) Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis. Antimicrob Agents Chemother 62:
Leblanc, Natalie M; Mitchell, Jason (2018) Providers' Perceptions of Couples' HIV Testing and Counseling (CHTC): Perspectives From a U.S. HIV Epicenter. Couple Family Psychol 7:22-33
Rice, John D; Johnson, Brent A; Strawderman, Robert L (2018) Modeling the rate of HIV testing from repeated binary data amidst potential never-testers. Biostatistics :
Nunn, Amy; Parker, Sharon; McCoy, Katryna et al. (2018) African American Clergy Perspectives About the HIV Care Continuum: Results From a Qualitative Study in Jackson, Mississippi. Ethn Dis 28:85-92
Sillman, Brady; Bade, Aditya N; Dash, Prasanta K et al. (2018) Creation of a long-acting nanoformulated dolutegravir. Nat Commun 9:443
Ogunbajo, Adedotun; Kershaw, Trace; Kushwaha, Sameer et al. (2018) Barriers, Motivators, and Facilitators to Engagement in HIV Care Among HIV-Infected Ghanaian Men Who have Sex with Men (MSM). AIDS Behav 22:829-839
Piekna-Przybylska, Dorota; Maggirwar, Sanjay B (2018) CD4+ memory T cells infected with latent HIV-1 are susceptible to drugs targeting telomeres. Cell Cycle 17:2187-2203
Ocque, Andrew J; Hagler, Colleen E; Morse, Gene D et al. (2018) Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid. J Pharm Biomed Anal 156:163-169
McMillan, JoEllyn; Szlachetka, Adam; Slack, Lara et al. (2018) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother 62:
Piekna-Przybylska, Dorota; Nagumotu, Kavyasri; Reid, Danielle M et al. (2018) HIV-1 infection renders brain vascular pericytes susceptible to the extracellular glutamate. J Neurovirol :

Showing the most recent 10 out of 192 publications